Top

Published in:

01-12-2013 | Research Article

The protein p17 signaling pathways in cancer

Author: Klaus Heese

Published in: Tumor Biology | Issue 6/2013

Abstract

P17 is a novel neuronal protein expressed under physiological conditions only at very low levels in other tissues. Accumulating data indicate its crucial involvement in tumorigenic effects. Using molecular, cellular, and biocomputational methods, the current study unraveled p17 mode of action. Data indicate that mitochondria-associated p17 interacts with the proteins TMEM115, YPEL3, ERP44, CDK5RAP, and NNAT. Moreover, p17 drives the cell cycle into the G0/G1 phase and enhances survival of proliferating cells. Interference with p17 activities thus might become a novel option to influence also the tumor suppressor protein p53 signaling pathways for the treatment of tumors.

Nehar S, Mishra M, Heese K. Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett. 2009;583(19):3247–53. doi:10.1016/j.febslet.2009.09.018.PubMedCrossRef

Guo C, Zhang X, Fink SP, Platzer P, Wilson K, Willson JK, et al. Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. Cancer Res. 2008;68(15):6118–26. doi:10.1158/0008-5472.CAN-08-1259.PubMedCrossRef

Wang LT, Lin CS, Chai CY, Liu KY, Chen JY, Hsu SH. Functional interaction of Ugene and EBV infection mediates tumorigenic effects. Oncogene. 2011;30(26):2921–32. doi:10.1038/onc.2011.16.PubMedCrossRef

Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266(24):15771–81.PubMed

Heese K, Yamada T, Akatsu H, Yamamoto T, Kosaka K, Nagai Y, et al. Characterizing the new transcription regulator protein p60TRP. J Cell Biochem. 2004;91(5):1030–42. doi:10.1002/jcb.20010.PubMedCrossRef

Mishra M, Akatsu H, Heese K. The novel protein MANI modulates neurogenesis and neurite-cone growth. J Cell Mol Med. 2011;15(8):1713–25. doi:10.1111/j.1582-4934.2010.01134.x.PubMedCrossRef

Mishra M, Inoue N, Heese K. Characterizing the novel protein p33MONOX. Mol Cell Biochem. 2011;350(1–2):127–34. doi:10.1007/s11010-010-0690-4.PubMedCrossRef

Mishra M, Heese K. P60TRP interferes with the GPCR/secretase pathway to mediate neuronal survival and synaptogenesis. J Cell Mol Med. 2011;15(11):2462–77. doi:10.1111/j.1582-4934.2010.01248.x.PubMedCrossRef

Islam O, Gong X, Rose-John S, Heese K. Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell. 2009;20(1):188–99. doi:10.1091/mbc.E08-05-0463.PubMedCrossRef

10.

Yokota T, Mishra M, Akatsu H, Tani Y, Miyauchi T, Yamamoto T, et al. Brain site-specific gene expression analysis in Alzheimer's disease patients. Eur J Clin Investig. 2006;36(11):820–30. doi:10.1111/j.1365-2362.2006.01722.x.CrossRef

11.

Heese K, Nagai Y, Sawada T. Induction of rat L-phosphoserine phosphatase by amyloid-beta (1-42) is inhibited by interleukin-11. Neurosci Lett. 2000;288(1):37–40.PubMedCrossRef

12.

Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ. YPEL3, a p53-regulated gene that induces cellular senescence. Cancer Res. 2010;70(9):3566–75. doi:10.1158/0008-5472.CAN-09-3219.PubMedCrossRef

13.

Berberich SJ, Todd A, Tuttle R. Why YPEL3 represents a novel tumor suppressor. Front Biosci. 2011;16:1746–51.CrossRef

14.

Tuttle R, Simon M, Hitch DC, Maiorano JN, Hellan M, Ouellette J, et al. Senescence-associated gene YPEL3 is downregulated in human colon tumors. Ann Surg Oncol. 2011;18(6):1791–6. doi:10.1245/s10434-011-1558-x.PubMedCrossRef

15.

Anelli T, Alessio M, Bachi A, Bergamelli L, Bertoli G, Camerini S, et al. Thiol-mediated protein retention in the endoplasmic reticulum: the role of ERp44. EMBO J. 2003;22(19):5015–22. doi:10.1093/emboj/cdg491.PubMedCrossRef

16.

Simmen T, Lynes EM, Gesson K, Thomas G. Oxidative protein folding in the endoplasmic reticulum: tight links to the mitochondria-associated membrane (MAM). Biochim Biophys Acta. 2010;1798(8):1465–73. doi:10.1016/j.bbamem.2010.04.009.PubMedCrossRef

17.

Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, Ng IO, et al. Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res. 2011;71(8):2949–58. doi:10.1158/0008-5472.CAN-10-4046.PubMedCrossRef

18.

Oyang EL, Davidson BC, Lee W, Poon MM. Functional characterization of the dendritically localized mRNA neuronatin in hippocampal neurons. PLoS One. 2011;6(9):e24879. doi:10.1371/journal.pone.0024879.PubMedCrossRef

19.

Akbari M, Otterlei M, Pena-Diaz J, Krokan HE. Different organization of base excision repair of uracil in DNA in nuclei and mitochondria and selective upregulation of mitochondrial uracil-DNA glycosylase after oxidative stress. Neuroscience. 2007;145(4):1201–12. doi:10.1016/j.neuroscience.2006.10.010.PubMedCrossRef

20.

Krokan HE, Otterlei M, Nilsen H, Kavli B, Skorpen F, Andersen S, et al. Properties and functions of human uracil-DNA glycosylase from the UNG gene. Prog Nucleic Acid Res Mol Biol. 2001;68:365–86.PubMedCrossRef

21.

Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, Skorpen F, et al. hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem. 2002;277(42):39926–36. doi:10.1074/jbc.M207107200.PubMedCrossRef

22.

Aravind L, Koonin EV. The alpha/beta fold uracil DNA glycosylases: a common origin with diverse fates. Genome Biol. 2000;1(4):RESEARCH0007. doi:10.1186/gb-2000-1-4-research0007.

23.

Mitra S. DNA glycosylases: specificity and mechanisms. Prog Nucleic Acid Res Mol Biol. 2001;68:189–92.PubMedCrossRef

24.

Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis. 2002;17(2):149–56.PubMedCrossRef

25.

Hoeijmakers JH. Genome maintenance mechanisms are critical for preventing cancer as well as other aging-associated diseases. Mech Ageing Dev. 2007;128(7–8):460–2. doi:10.1016/j.mad.2007.05.002.PubMedCrossRef

26.

Hang B, Singer B. Protein-protein interactions involving DNA glycosylases. Chem Res Toxicol. 2003;16(10):1181–95. doi:10.1021/tx030020p.PubMedCrossRef

27.

Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, et al. Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene. 2001;20(5):581–9. doi:10.1038/sj.onc.1204120.PubMedCrossRef

28.

Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair. EMBO J. 2001;20(4):914–23. doi:10.1093/emboj/20.4.914.PubMedCrossRef

29.

Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morphol. 2012;45(3):115–23. doi:10.1007/s00795-012-0575-6.PubMedCrossRef

30.

Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol. 2012;30(29):3648–50. doi:10.1200/JCO.2012.44.0412.PubMedCrossRef

31.

Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012;19(12):1992–2002. doi:10.1038/cdd.2012.89.PubMedCrossRef

32.

Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol. 2012;2012:170325. doi:10.1155/2012/170325.PubMed

33.

da Costa PE, Cavalli LR, Rainho CA. Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics. 2011;6(12):1413–24. doi:10.4161/epi.6.12.18271.CrossRef

34.

Tuttle R, Miller KR, Maiorano JN, Termuhlen PM, Gao Y, Berberich SJ. Novel senescence associated gene, YPEL3, is repressed by estrogen in ER+ mammary tumor cells and required for tamoxifen-induced cellular senescence. Int J Cancer. 2012;130(10):2291–9. doi:10.1002/ijc.26239.PubMedCrossRef

35.

Berberich SJ. RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling. Cell Cycle. 2010;9(18):3640–1.PubMedCrossRef

36.

Hubertus J, Lacher M, Rottenkolber M, Muller-Hocker J, Berger M, Stehr M, et al. Altered expression of imprinted genes in Wilms tumors. Oncol Rep. 2011;25(3):817–23. doi:10.3892/or.2010.1113.PubMed

37.

Kaushal M, Mishra AK, Sharma J, Zomawia E, Kataki A, Kapur S, et al. Genomic alterations in breast cancer patients in betel quid and non betel quid chewers. PLoS One. 2012;7(8):e43789. doi:10.1371/journal.pone.0043789.PubMedCrossRef

38.

Kuerbitz SJ, Pahys J, Wilson A, Compitello N, Gray TA. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis. 2002;23(4):559–64.PubMedCrossRef

39.

Schulz R, McCole RB, Woodfine K, Wood AJ, Chahal M, Monk D, et al. Transcript- and tissue-specific imprinting of a tumour suppressor gene. Hum Mol Genet. 2009;18(1):118–27. doi:10.1093/hmg/ddn322.PubMedCrossRef

40.

Evans HK, Wylie AA, Murphy SK, Jirtle RL. The neuronatin gene resides in a “micro-imprinted” domain on human chromosome 20q11.2. Genomics. 2001;77(1–2):99–104.PubMedCrossRef

41.

Uchihara T, Okubo C, Tanaka R, Minami Y, Inadome Y, Iijima T, et al. Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma. J Thorac Oncol. 2007;2(9):796–801. doi:10.1097/JTO.0b013e318145af5e.PubMedCrossRef

42.

Siu IM, Bai R, Gallia GL, Edwards JB, Tyler BM, Eberhart CG, et al. Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol. 2008;10(5):716–24. doi:10.1215/15228517-2008-038.PubMedCrossRef

43.

Xu DS, Yang C, Proescholdt M, Brundl E, Brawanski A, Fang X, et al. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS One. 2012;7(5):e37811. doi:10.1371/journal.pone.0037811.PubMedCrossRef

44.

Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal. 2012;24(1):44–52. doi:10.1016/j.cellsig.2011.08.022.PubMedCrossRef

45.

Rosales JL, Lee KY. Extraneuronal roles of cyclin-dependent kinase 5. Bioessays. 2006;28(10):1023–34. doi:10.1002/bies.20473.PubMedCrossRef

46.

Arif A. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem Pharmacol. 2012;84(8):985–93. doi:10.1016/j.bcp.2012.06.027.PubMedCrossRef

47.

Stav D, Bar I, Sandbank J. Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. Int J Biol Markers. 2007;22(2):108–13.PubMed

48.

Lu X, Bocangel D, Nannenga B, Yamaguchi H, Appella E, Donehower LA. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell. 2004;15(4):621–34. doi:10.1016/j.molcel.2004.08.007.PubMedCrossRef

49.

Lu X, Nguyen TA, Appella E, Donehower LA. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004;3(11):1363–6.PubMedCrossRef

50.

Macurek L, Benada J, Mullers E, Halim VA, Krejcikova K, Burdova K et al. Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis. Cell Cycle. 2013;12(2): 251–62. doi: 10.4161/cc.23057.

51.

Park HK, Panneerselvam J, Dudimah FD, Dong G, Sebastian S, Zhang J, et al. Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53. Cell Cycle. 2011;10(15):2574–82.PubMedCrossRef

52.

Lowe J, Cha H, Lee MO, Mazur SJ, Appella E, Fornace Jr AJ. Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci. 2012;17:1480–98.CrossRef

53.

Gaiddon C, Moorthy NC, Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J. 1999;18(20):5609–21. doi:10.1093/emboj/18.20.5609.PubMedCrossRef

54.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2012;493(7432):406–10. doi:10.1038/nature11725.PubMedCrossRef

Title: The protein p17 signaling pathways in cancer
Author: Klaus Heese
Publication date: 01-12-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0999-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

RETRACTED ARTICLE: Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis

Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate

Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency

PLCE1 rs2274223 A>G polymorphism and cancer risk: a meta-analysis

MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer